The DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index.
CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment
Open accessAbstract
Chimeric antigen receptor (CAR) T cells, T cells that have been genetically engineered to express a receptor that recognizes a specific antigen, have given rise to breakthroughs in treating hematological malignancies. However, their success in treating solid tumors has been limited. The unique challenges posed to CAR T cell therapy by solid tumors can be described in three steps: finding, entering, and surviving in the tumor. The use of dual CAR designs that recognize multiple antigens at once and local administration of CAR T cells are both strategies that have been used to overcome the hurdle of localization to the tumor. Additionally, the immunosuppressive tumor microenvironment has implications for T cell function in terms of differentiation and exhaustion, and combining CARs with checkpoint blockade or depletion of other suppressive factors in the microenvironment has shown very promising results to mitigate the phenomenon of T cell exhaustion. Finally, identifying and overcoming mechanisms associated with dysfunction in CAR T cells is of vital importance to generating CAR T cells that can proliferate and successfully eliminate tumor cells. The structure and costimulatory domains chosen for the CAR may play an important role in the overall function of CAR T cells in the TME, and "armored" CARs that secrete cytokines and third- and fourth-generation CARs with multiple costimulatory domains offer ways to enhance CAR T cell function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 5×
“The tumor microenvironment also relies on stromal cells like cancer associated fibroblasts (CAFs) and suppressive immune cells, including myeloid-derived suppressor cells (MDSCs), tumor associated macrophages (TAMs), tumor associated neutrophils (TANs), mast cells, and regulatory T cells (Tregs) (Figure 2) (95).”
BackgroundInfluentialMetabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
A human memory T cell subset with stem cell–like properties
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974 · cited 2×
“(154) above, except for the expression of CD45R0.”
BackgroundRegression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,836
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · cited 1×
“A study with a CD19/28ζ CAR used CRISPR to insert the CAR under the control of the TCR promoter (at the TRAC locus), while simultaneously knocking out the TCR via insertion of the CAR gene (182).”
MethodO’Rourke, D. M., Nasrallah, M. P., Desai, A., Melenhorst, J. J., Mansfield, K., Morrissette, J. J. D., Martinez-Lage, M., Brem, S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,803
Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785
Langer, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30498-3 · Cited by 1,404
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368
Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,254
Kawalekar, O. U., O’Connor, R. S., Fraietta, J. A., Guo, L., McGettigan, S. E., Posey, A. D., Patel, P. R., Guedan, S., Scholler, J., Keith, B., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.021 · Cited by 1,230
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., et al. (2017) · Nature · doi:10.1038/nature24462 · Cited by 1,191
Thommen, D. S., Koelzer, V. H., Herzig, P., Roller, A., Trefny, M., Dimeloe, S., Kiialainen, A., Hanhart, J., Schill, C., Hess, C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0057-z · Cited by 1,161 · cited 1×
“In a recent analysis of varied NSCLC patient samples, a population of CD8 TILs with high PD-1 expression did not appear exhausted, and genes involved in cycling and proliferation such as Ki-67, as well as genes involved in trafficking and metabolism, were upregulated (147).”
BackgroundKumar, B. V., Ma, W., Miron, M., Granot, T., Guyer, R. S., Carpenter, D. J., Senda, T., Sun, X., Ho, S.-H., Lerner, H., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.078 · Cited by 1,068
Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in lymphocytes
Mackay, L. K., Minnich, M., Kragten, N. A. M., Liao, Y., Nota, B., Seillet, C., Zaid, A., Man, K., Preston, S., Freestone, D., et al. (2016) · Science · doi:10.1126/science.aad2035 · Cited by 1,010
CAR T Cell Therapy for Solid Tumors
Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909
Self-citationMolecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., Somana, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj2013 · Cited by 902
Beatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., Chew, A., Zhao, Y., Levine, B. L., Albelda, S. M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0170 · Cited by 864
Ahmed, N., Brawley, V., Hegde, M., Bielamowicz, K., Kalra, M., Landi, D., Robertson, C., Gray, T. L., Diouf, O., Wakefield, A., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0184 · Cited by 850
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Rafiq, S., Yeku, O. O., Jackson, H. J., Purdon, T. J., van Leeuwen, D. G., Drakes, D. J., Song, M., Miele, M. M., Li, Z., Wang, P., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4195 · Cited by 833 · cited 1×
“A similar study also used MUC16-ecto targeting CARs secreting anti-PD-1 scFvs in syngeneic and xenograft mouse models of PD-L1metastatic ovarian cancers, and showed superiority over CAR T cells plus PD-1 checkpoint inhibitors (134).”
MethodAdachi, K., Kano, Y., Nagai, T., Okuyama, N., Sakoda, Y., & Tamada, K. (2018) · Nature Biotechnology · doi:10.1038/nbt.4086 · Cited by 792
Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-00462-8 · Cited by 757
Todaro, M., Gaggianesi, M., Catalano, V., Benfante, A., Iovino, F., Biffoni, M., Apuzzo, T., Sperduti, I., Volpe, S., Cocorullo, G., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.01.009 · Cited by 717
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
Hegde, M., Mukherjee, M., Grada, Z., Pignata, A., Landi, D., Navai, S. A., Wakefield, A., Fousek, K., Bielamowicz, K., Chow, K. K. H., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83416 · Cited by 677
Wang, L.-C. S., Lo, A., Scholler, J., Sun, J., Majumdar, R. S., Kapoor, V., Antzis, M., Cotner, C. E., Johnson, L. A., Durham, A. C., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0027 · Cited by 653
Targeting VEGF/VEGFR to modulate antitumor immunity
Yang, J., Yan, J., & Liu, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00978 · Cited by 646
IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors
Cieri, N., Camisa, B., Cocchiarella, F., Forcato, M., Oliveira, G., Provasi, E., Bondanza, A., Bordignon, C., Peccatori, J., Ciceri, F., et al. (2013) · Blood · doi:10.1182/blood-2012-05-431718 · Cited by 625
T memory stem cells in health and disease
Gattinoni, L., Speiser, D. E., Lichterfeld, M., & Bonini, C. (2017) · Nature Medicine · doi:10.1038/nm.4241 · Cited by 620
Zhang, Y., Kurupati, R., Liu, L., Zhou, X. Y., Zhang, G., Hudaihed, A., Filisio, F., Giles-Davis, W., Xu, X., Karakousis, G. C., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.08.004 · Cited by 616
Mackay, L. K., Wynne-Jones, E., Freestone, D., Pellicci, D. G., Mielke, L. A., Newman, D. M., Braun, A., Masson, F., Kallies, A., Belz, G. T., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.11.008 · Cited by 607
Zah, E., Lin, M.-Y., Silva-Benedict, A., Jensen, M. C., & Chen, Y. Y. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0231 · Cited by 607
Wang, X., Chang, W.-C., Wong, C. W., Colcher, D., Sherman, M., Ostberg, J. R., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2011) · Blood · doi:10.1182/blood-2011-02-337360 · Cited by 600
Molecular regulation of effector and memory T cell differentiation
Chang, J. T., Wherry, E. J., & Goldrath, A. W. (2014) · Nature Immunology · doi:10.1038/ni.3031 · Cited by 582
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
Guedan, S., Posey, A. D., Shaw, C., Wing, A., Da, T., Patel, P. R., McGettigan, S. E., Casado-Medrano, V., Kawalekar, O. U., Uribe-Herranz, M., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96976 · Cited by 580
Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells
Fuhlbrigge, R. C., Kieffer, J. D., Armerding, D., & Kupper, T. S. (1997) · Nature · doi:10.1038/40166 · Cited by 577
Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy
Golubovskaya, V., & Wu, L. (2016) · Cancers · doi:10.3390/cancers8030036 · Cited by 577
Moon, E. K., Carpenito, C., Sun, J., Wang, L.-C. S., Kapoor, V., Predina, J., Powell, D. J., Riley, J. L., June, C. H., & Albelda, S. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0351 · Cited by 537
Self-citationGanesan, A.-P., Clarke, J., Wood, O., Garrido-Martin, E. M., Chee, S. J., Mellows, T., Samaniego-Castruita, D., Singh, D., Seumois, G., Alzetani, A., et al. (2017) · Nature Immunology · doi:10.1038/ni.3775 · Cited by 528
Liu, X., Ranganathan, R., Jiang, S., Fang, C., Sun, J., Kim, S., Newick, K., Lo, A., June, C. H., Zhao, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2524 · Cited by 523
Self-citationRunx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs
Cruz-Guilloty, F., Pipkin, M. E., Djuretic, I. M., Levanon, D., Lotem, J., Lichtenheld, M. G., Groner, Y., & Rao, A. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081242 · Cited by 520
Craddock, J. A., Lu, A., Bear, A., Pule, M., Brenner, M. K., Rooney, C. M., & Foster, A. E. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ee6675 · Cited by 513
PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR
Chong, E. A., Melenhorst, J. J., Lacey, S. F., Ambrose, D. E., Gonzalez, V., Levine, B. L., June, C. H., & Schuster, S. J. (2017) · Blood · doi:10.1182/blood-2016-09-738245 · Cited by 496
Salter, A. I., Ivey, R. G., Kennedy, J. J., Voillet, V., Rajan, A., Alderman, E. J., Voytovich, U. J., Lin, C., Sommermeyer, D., Liu, L., et al. (2018) · Science Signaling · doi:10.1126/scisignal.aat6753 · Cited by 495
Wilkie, S., van Schalkwyk, M. C. I., Hobbs, S., Davies, D. M., van der Stegen, S. J. C., Pereira, A. C. P., Burbridge, S. E., Box, C., Eccles, S. A., & Maher, J. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9689-9 · Cited by 478
Tran, E., Chinnasamy, D., Yu, Z., Morgan, R. A., Lee, C.-C. R., Restifo, N. P., & Rosenberg, S. A. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130110 · Cited by 463
Tchou, J., Zhao, Y., Levine, B. L., Zhang, P. J., Davis, M. M., Melenhorst, J. J., Kulikovskaya, I., Brennan, A. L., Liu, X., Lacey, S. F., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0189 · Cited by 452
Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer
Provasi, E., Genovese, P., Lombardo, A., Magnani, Z., Liu, P.-Q., Reik, A., Chu, V., Paschon, D. E., Zhang, L., Kuball, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2700 · Cited by 448
Chmielewski, M., & Abken, H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.063 · Cited by 429
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
Koneru, M., Purdon, T. J., Spriggs, D., Koneru, S., & Brentjens, R. J. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.994446 · Cited by 418
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
Yeku, O. O., Purdon, T. J., Koneru, M., Spriggs, D., & Brentjens, R. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-10940-8 · Cited by 409
Thistlethwaite, F. C., Gilham, D. E., Guest, R. D., Rothwell, D. G., Pillai, M., Burt, D. J., Byatte, A. J., Kirillova, N., Valle, J. W., Sharma, S. K., et al. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2034-7 · Cited by 406
Moon, E. K., Wang, L.-C., Dolfi, D. V., Wilson, C. B., Ranganathan, R., Sun, J., Kapoor, V., Scholler, J., Puré, E., Milone, M. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2627 · Cited by 404
Self-citationA versatile system for rapid multiplex genome-edited CAR T cell generation
Ren, J., Zhang, X., Liu, X., Fang, C., Jiang, S., June, C. H., & Zhao, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.15218 · Cited by 397
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
Thomas, R., Al-Khadairi, G., Roelands, J., Hendrickx, W., Dermime, S., Bedognetti, D., & Decock, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00947 · Cited by 393
Siska, P. J., Beckermann, K. E., Mason, F. M., Andrejeva, G., Greenplate, A. R., Sendor, A. B., Chiang, Y.-C. J., Corona, A. L., Gemta, L. F., Vincent, B. G., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93411 · Cited by 389
A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
Ohta, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00109 · Cited by 385
Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes
Cohen, C. J., Gartner, J. J., Horovitz-Fried, M., Shamalov, K., Trebska-McGowan, K., Bliskovsky, V. V., Parkhurst, M. R., Ankri, C., Prickett, T. D., Crystal, J. S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82416 · Cited by 374
Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment
Renner, K., Singer, K., Koehl, G. E., Geissler, E. K., Peter, K., Siska, P. J., & Kreutz, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00248 · Cited by 374
The Molecular Signature of Tissue Resident Memory CD8 T Cells Isolated from the Brain
Wakim, L. M., Woodward-Davis, A., Liu, R., Hu, Y., Villadangos, J., Smyth, G., & Bevan, M. J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201305 · Cited by 363
Sul, J., Blumenthal, G. M., Jiang, X., He, K., Keegan, P., & Pazdur, R. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0498 · Cited by 359
Gargett, T., Yu, W., Dotti, G., Yvon, E. S., Christo, S. N., Hayball, J. D., Lewis, I. D., Brenner, M. K., & Brown, M. P. (2016) · Molecular Therapy · doi:10.1038/mt.2016.63 · Cited by 358
Han, J., Chu, J., Keung Chan, W., Zhang, J., Wang, Y., Cohen, J. B., Victor, A., Meisen, W. H., Kim, S.-H., Grandi, P., et al. (2015) · Scientific Reports · doi:10.1038/srep11483 · Cited by 340
Suarez, E. R., Chang, D.-K., Sun, J., Sui, J., Freeman, G. J., Signoretti, S., Zhu, Q., & Marasco, W. A. (2016) · Oncotarget · doi:10.18632/oncotarget.9114 · Cited by 340
Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas
Long, A. H., Highfill, S. L., Cui, Y., Smith, J. P., Walker, A. J., Ramakrishna, S., El-Etriby, R., Galli, S., Tsokos, M. G., Orentas, R. J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0230 · Cited by 329
Priceman, S. J., Tilakawardane, D., Jeang, B., Aguilar, B., Murad, J. P., Park, A. K., Chang, W.-C., Ostberg, J. R., Neman, J., Jandial, R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2041 · Cited by 327
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
Beavis, P. A., Henderson, M. A., Giuffrida, L., Mills, J. K., Sek, K., Cross, R. S., Davenport, A. J., John, L. B., Mardiana, S., Slaney, C. Y., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89455 · Cited by 325
Wang, X., Popplewell, L. L., Wagner, J. R., Naranjo, A., Blanchard, M. S., Mott, M. R., Norris, A. P., Wong, C. W., Urak, R. Z., Chang, W.-C., et al. (2016) · Blood · doi:10.1182/blood-2015-12-686725 · Cited by 322
Krenciute, G., Prinzing, B. L., Yi, Z., Wu, M.-F., Liu, H., Dotti, G., Balyasnikova, I. V., & Gottschalk, S. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0376 · Cited by 319
High-Resolution Genome-Wide Mapping of Transposon Integration in Mammals
Yant, S. R., Wu, X., Huang, Y., Garrison, B., Burgess, S. M., & Kay, M. A. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.6.2085-2094.2005 · Cited by 318
Toward eliminating HLA class I expression to generate universal cells from allogeneic donors
Torikai, H., Reik, A., Soldner, F., Warren, E. H., Yuen, C., Zhou, Y., Crossland, D. L., Huls, H., Littman, N., Zhang, Z., et al. (2013) · Blood · doi:10.1182/blood-2013-03-478255 · Cited by 311
Induction of resident memory T cells enhances the efficacy of cancer vaccine
Nizard, M., Roussel, H., Diniz, M. O., Karaki, S., Tran, T., Voron, T., Dransart, E., Sandoval, F., Riquet, M., Rance, B., et al. (2017) · Nature Communications · doi:10.1038/ncomms15221 · Cited by 308
Chimeric antigen receptor T cells: a novel therapy for solid tumors
Yu, S., Li, A., Liu, Q., Li, T., Yuan, X., Han, X., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0444-9 · Cited by 306
Li, S., Siriwon, N., Zhang, X., Yang, S., Jin, T., He, F., Kim, Y. J., Mac, J., Lu, Z., Wang, S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0867 · Cited by 300
Beatty, G. L., Winograd, R., Evans, R. A., Long, K. B., Luque, S. L., Lee, J. W., Clendenin, C., Gladney, W. L., Knoblock, D. M., Guirnalda, P. D., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.010 · Cited by 293
The Immune Revolution: A Case for Priming, Not Checkpoint
Vonderheide, R. H. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.008 · Cited by 293
Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies
Ruella, M., & Maus, M. V. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.09.003 · Cited by 285
Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists
Zheng, Y., Qin, L., Zacarías, N. V. O., de Vries, H., Han, G. W., Gustavsson, M., Dabros, M., Zhao, C., Cherney, R. J., Carter, P., et al. (2016) · Nature · doi:10.1038/nature20605 · Cited by 284
Mohammed, S., Sukumaran, S., Bajgain, P., Watanabe, N., Heslop, H. E., Rooney, C. M., Brenner, M. K., Fisher, W. E., Leen, A. M., & Vera, J. F. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.016 · Cited by 281
Chinnasamy, D., Yu, Z., Kerkar, S. P., Zhang, L., Morgan, R. A., Restifo, N. P., & Rosenberg, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3050 · Cited by 277
Richman, S. A., Nunez-Cruz, S., Moghimi, B., Li, L. Z., Gershenson, Z. T., Mourelatos, Z., Barrett, D. M., Grupp, S. A., & Milone, M. C. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0211 · Cited by 267
T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma
Chow, K. K., Naik, S., Kakarla, S., Brawley, V. S., Shaffer, D. R., Yi, Z., Rainusso, N., Wu, M.-F., Liu, H., Kew, Y., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.210 · Cited by 245
CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells
Zhang, Y., Zhang, X., Cheng, C., Mu, W., Liu, X., Li, N., Wei, X., Liu, X., Xia, C., & Wang, H. (2017) · Frontiers of Medicine · doi:10.1007/s11684-017-0543-6 · Cited by 239
Yeku, O. O., & Brentjens, R. J. (2016) · Biochemical Society Transactions · doi:10.1042/bst20150291 · Cited by 237
CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells
Legut, M., Dolton, G., Mian, A. A., Ottmann, O. G., & Sewell, A. K. (2018) · Blood · doi:10.1182/blood-2017-05-787598 · Cited by 228
An oxygen sensitive self-decision making engineered CAR T-cell
Juillerat, A., Marechal, A., Filhol, J. M., Valogne, Y., Valton, J., Duclert, A., Duchateau, P., & Poirot, L. (2017) · Scientific Reports · doi:10.1038/srep39833 · Cited by 225
Ligtenberg, M. A., Mougiakakos, D., Mukhopadhyay, M., Witt, K., Lladser, A., Chmielewski, M., Riet, T., Abken, H., & Kiessling, R. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1401710 · Cited by 218
Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
Gulley, J. L., Madan, R. A., Pachynski, R., Mulders, P., Sheikh, N. A., Trager, J., & Drake, C. G. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djw261 · Cited by 215
T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy
Sackstein, R., Schatton, T., & Barthel, S. R. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.25 · Cited by 215
Yoon, D., Osborn, M., Tolar, J., & Kim, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020340 · Cited by 215
Jiang, Z., Jiang, X., Chen, S., Lai, Y., Wei, X., Li, B., Lin, S., Wang, S., Wu, Q., Liang, Q., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00690 · Cited by 207
Schuberth, P. C., Hagedorn, C., Jensen, S. M., Gulati, P., van den Broek, M., Mischo, A., Soltermann, A., Jüngel, A., Marroquin Belaunzaran, O., Stahel, R., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-187 · Cited by 206
Improving the safety of cell therapy products by suicide gene transfer
Jones, B. S., Lamb, L. S., Goldman, F., & Di Stasi, A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00254 · Cited by 201
Martinet, L., Le Guellec, S., Filleron, T., Lamant, L., Meyer, N., Rochaix, P., Garrido, I., & Girard, J.-P. (2012) · OncoImmunology · doi:10.4161/onci.20492 · Cited by 193
Chronic Antigen Stimulation Alone Is Sufficient to Drive CD8+ T Cell Exhaustion
Bucks, C. M., Norton, J. A., Boesteanu, A. C., Mueller, Y. M., & Katsikis, P. D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0800997 · Cited by 187
Yu, J., Wu, X., Yan, J., Yu, H., Xu, L., Chi, Z., Sheng, X., Si, L., Cui, C., Dai, J., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0548-2 · Cited by 184
Lack of immunoediting in murine pancreatic cancer reversed with neoantigen
Evans, R. A., Diamond, M. S., Rech, A. J., Chao, T., Richardson, M. W., Lin, J. H., Bajor, D. L., Byrne, K. T., Stanger, B. Z., Riley, J. L., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88328 · Cited by 180
Ager, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00045 · Cited by 179
Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery
Katz, S. C., Point, G. R., Cunetta, M., Thorn, M., Guha, P., Espat, N. J., Boutros, C., Hanna, N., & Junghans, R. P. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.14 · Cited by 177
Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases
Corbière, V., Chapiro, J., Stroobant, V., Ma, W., Lurquin, C., Lethé, B., van Baren, N., Van den Eynde, B. J., Boon, T., & Coulie, P. G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2693 · Cited by 175
Moon, E. K., Wang, L.-C. S., Bekdache, K., Lynn, R. C., Lo, A., Thorne, S. H., & Albelda, S. M. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1395997 · Cited by 174
Self-citationCao, J., Wang, G., Cheng, H., Wei, C., Qi, K., Sang, W., Zhenyu, L., Shi, M., Li, H., Qiao, J., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25108 · Cited by 173
Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses
Oliver, A. J., Lau, P. K. H., Unsworth, A. S., Loi, S., Darcy, P. K., Kershaw, M. H., & Slaney, C. Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00070 · Cited by 169
Lamers, C. H. J., Klaver, Y., Gratama, J. W., Sleijfer, S., & Debets, R. (2016) · Biochemical Society Transactions · doi:10.1042/bst20160037 · Cited by 168
Priceman, S. J., Gerdts, E. A., Tilakawardane, D., Kennewick, K. T., Murad, J. P., Park, A. K., Jeang, B., Yamaguchi, Y., Yang, X., Urak, R., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1380764 · Cited by 166
Park, S., Shevlin, E., Vedvyas, Y., Zaman, M., Park, S., Hsu, Y.-M. S., Min, I. M., & Jin, M. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-14749-3 · Cited by 163
Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma
Quintarelli, C., Orlando, D., Boffa, I., Guercio, M., Polito, V. A., Petretto, A., Lavarello, C., Sinibaldi, M., Weber, G., Del Bufalo, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1433518 · Cited by 163
Lo, A., Li, C.-P., Buza, E. L., Blomberg, R., Govindaraju, P., Avery, D., Monslow, J., Hsiao, M., & Puré, E. (2017) · JCI Insight · doi:10.1172/jci.insight.92232 · Cited by 160
Driving T-cell immunotherapy to solid tumors
Garber, K. (2018) · Nature Biotechnology · doi:10.1038/nbt.4090 · Cited by 159
Blaeschke, F., Stenger, D., Kaeuferle, T., Willier, S., Lotfi, R., Kaiser, A. D., Assenmacher, M., Döring, M., Feucht, J., & Feuchtinger, T. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2155-7 · Cited by 155
miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy
Huang, Q., Xia, J., Wang, L., Wang, X., Ma, X., Deng, Q., Lu, Y., Kumar, M., Zhou, Z., Li, L., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0600-x · Cited by 151
Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
Tomasini, P., Walia, P., Labbé, C., Jao, K., & Leighl, N. B. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0084 · Cited by 147
Mejstříková, E., Hrušák, O., Borowitz, M. J., Whitlock, J. A., Brethon, B., Trippett, T. M., Zugmaier, G., Gore, L., von Stackelberg, A., & Locatelli, F. (2017) · Blood Cancer Journal · doi:10.1038/s41408-017-0023-x · Cited by 147
Nellan, A., Rota, C., Majzner, R. G., McCully, C. L., Griesinger, A. M., Levy, J. M. M., Foreman, N. K., Warren, K. E., & Lee, D. W. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0340-z · Cited by 145
Magee, M. S., Abraham, T. S., Baybutt, T. R., Flickinger, J. C., Ridge, N. A., Marszalowicz, G. P., Prajapati, P., Hersperger, A. R., Waldman, S. A., & Snook, A. E. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0362 · Cited by 143
Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf
Ruella, M., & Kenderian, S. S. (2017) · BioDrugs · doi:10.1007/s40259-017-0247-0 · Cited by 136
CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy
Chen, N., Morello, A., Tano, Z. E., & Adusumilli, P. S. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1273302 · Cited by 134
Morrot, A., da Fonseca, L. M., Salustiano, E. J., Gentile, L. B., Conde, L., Filardy, A. A., Franklim, T. N., da Costa, K. M., Freire-de-Lima, C. G., & Freire‐de‐Lima, L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00081 · Cited by 134
Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma
Yi, Z., Prinzing, B. L., Cao, F., Gottschalk, S. M., & Krenciute, G. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.009 · Cited by 131
Ankyrin protein networks in membrane formation and stabilization
Cunha, S. R., & Mohler, P. J. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00943.x · Cited by 130
An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes
Bjerregaard, A.-M., Nielsen, M., Jurtz, V. I., Barra, C., Hadrup, S. R., Szállási, Z., & Eklund, A. C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01566 · Cited by 128
Construction and evaluation of a novel humanized HER2-specific chimeric receptor
Sun, M., Shi, H., Liu, C., Liu, J., Liu, X., & Sun, Y. (2014) · Breast Cancer Research · doi:10.1186/bcr3674 · Cited by 125
Armed and Ready: Transcriptional Regulation of Tissue-Resident Memory CD8 T Cells
Behr, F. M., Chuwonpad, A., Stark, R., & van Gisbergen, K. P. J. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01770 · Cited by 124
Hu, B., Zou, Y., Zhang, L., Tang, J., Niedermann, G., Firat, E., Huang, X., & Zhu, X. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.234 · Cited by 124
Translating Sleeping Beauty transposition into cellular therapies: Victories and challenges
Izsvák, Z., Hackett, P. B., Cooper, L. J. N., & Ivics, Z. (2010) · BioEssays · doi:10.1002/bies.201000027 · Cited by 120
Poggi, A. D., Varesano, S., & Zocchi, M. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00262 · Cited by 117
Li, H., Huang, Y. Q., Jiang, D., Cui, L., He, Z., Wang, C., Zhang, Z., Zhu, H., Ding, Y., Li, L., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0238-6 · Cited by 117
Gargett, T., & Brown, M. P. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2014.12.002 · Cited by 115
Lehner, M., Götz, G., Proff, J., Schaft, N., Dörrie, J., Full, F., Ensser, A., Muller, Y. A., Cerwenka, A., Abken, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031210 · Cited by 111
CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation
Bajgain, P., Tawinwung, S., Fleckenstein, L., Sukumaran, S., Watanabe, N., Hoyos, V., Lulla, P., Brenner, M. K., Leen, A. M., & Vera, J. F. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0347-5 · Cited by 110
Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9
Ren, J., & Zhao, Y. (2017) · Protein & Cell · doi:10.1007/s13238-017-0410-x · Cited by 108
Metabolic Reprogramming and Longevity of Tissue-Resident Memory T Cells
Pan, Y., & Kupper, T. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01347 · Cited by 106
Ang, W. X., Li, Q., Chi, Z., Du, S., Chen, C., Tay, J. C.-K., Toh, H. C., Connolly, J. E., Xu, X., & Wang, S. (2017) · Oncotarget · doi:10.18632/oncotarget.14592 · Cited by 104
Lieber, S., Reinartz, S., Raifer, H., Finkernagel, F., Dreyer, T. F., Bronger, H., Jansen, J. M., Wagner, U. A. G., Worzfeld, T., Müller, R., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1424672 · Cited by 103
CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors
Min, I. M., Shevlin, E., Vedvyas, Y., Zaman, M., Wyrwas, B., Scognamiglio, T., Moore, M. D., Wang, W., Park, S., Park, S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2008 · Cited by 99
Macrophages facilitate resistance to anti-VEGF therapy by altered VEGFR expression
Dalton, H. J., Pradeep, S., McGuire, M., Hailemichael, Y., MA, S., Lyons, Y., Armaiz-Pena, G. N., Previs, R. A., Hansen, J. M., Rupaimoole, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0647 · Cited by 97
Pituch, K. C., Miska, J. M., Krenciute, G., Panek, W. K., Li, G., Rodríguez-Cruz, T., Wu, M., Han, Y., Lesniak, M. S., Gottschalk, S. M., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.001 · Cited by 94
A TCR-based Chimeric Antigen Receptor
Walseng, E., Köksal, H., Sektioglu, I. M., Fåne, A., Skorstad, G., Kvalheim, G., Gaudernack, G., Inderberg, E. M., & Wälchli, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-11126-y · Cited by 93
Wei, C.-H., Wu, G., Cai, Q., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0546-4 · Cited by 91
Daenen, L. G. M., Shaked, Y., Man, S., Xu, P., Voest, E. E., Hoffman, R. M., Chaplin, D. J., & Kerbel, R. S. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0583 · Cited by 90
Mesothelin as a Target for Chimeric Antigen Receptor-Modified T Cells as Anticancer Therapy
O’Hara, M. H., Stashwick, C., Haas, A. R., & Tanyi, J. L. (2016) · Immunotherapy · doi:10.2217/imt.16.4 · Cited by 90
Efficacy of CAR T-cell Therapy in Large Tumors Relies upon Stromal Targeting by IFNγ
Textor, A., Listopad, J. J., Wührmann, L. L., Pérez, C., Kruschinski, A., Chmielewski, M. M., Abken, H., Blankenstein, T. J. F., & Charo, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0079 · Cited by 88
Kistner, L., Doll, D., Holtorf, A., Nitsche, U., & Janssen, K. (2017) · Oncotarget · doi:10.18632/oncotarget.21286 · Cited by 80
CD160-Associated CD8 T-Cell Functional Impairment Is Independent of PD-1 Expression
Viganó, S., Banga, R., Bellanger, F., Pellaton, C., Farina, A., Comte, D., Harari, A., & Perreau, M. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004380 · Cited by 79
Wei, G., Ding, L., Wang, J., Hu, Y., & Huang, H. (2017) · Experimental Hematology and Oncology · doi:10.1186/s40164-017-0070-9 · Cited by 78
Wu, L., Yun, Z., Tagawa, T., Rey‐McIntyre, K., & de Perrot, M. E. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-1014 · Cited by 76
Kim, S., Lee, S., Lee, C. H., Lee, M. K., Kim, Y. D., Shin, D., Choi, K. U., Kim, J. Y., Park, D. Y., & Sol, M. Y. (2009) · Lung · doi:10.1007/s00408-009-9181-3 · Cited by 74
Runx3-mediated Transcriptional Program in Cytotoxic Lymphocytes
Lotem, J., Levanon, D., Negreanu, V., Leshkowitz, D., Friedlander, G., & Groner, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080467 · Cited by 73
T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities
Wang, Z., Li, B., Ren, Y., & Ye, Z. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00353 · Cited by 73
Tosch, C., Bastien, B., Barraud, L., Grellier, B., Nourtier, V., Gantzer, M., Limacher, J. M., Quéméneur, É., Bendjama, K., & Préville, X. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0274-x · Cited by 73
Karasaki, T., Nagayama, K., Kuwano, H., Nitadori, J., Sato, M., Anraku, M., Hosoi, A., Matsushita, H., Takazawa, M., Ohara, O., et al. (2016) · Cancer Science · doi:10.1111/cas.13131 · Cited by 71
Wu, X., Li, J., Connolly, E. M., Liao, X., Ouyang, J., Giobbie‐Hurder, A., Lawrence, D. P., McDermott, D. F., Murphy, G. F., Zhou, J. M., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0385 · Cited by 71
CAR-T cell therapy in ovarian cancer: from the bench to the bedside
Zhu, X., Cai, H., Zhao, L., Ning, L., & Lang, J. (2017) · Oncotarget · doi:10.18632/oncotarget.19929 · Cited by 69
CAR T-cell immunotherapy of MET-expressing malignant mesothelioma
Thayaparan, T., Petrovic, R. M., Achkova, D., Zabinski, T., Davies, D. M., Klampatsa, A., Parente‐Pereira, A. C., Whilding, L. M., van der Stegen, S. J. C., Woodman, N. L., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1363137 · Cited by 68
Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering
Han, X., Cinay, G. E., Zhao, Y., Guo, Y., Zhang, X., & Wang, P. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.07.009 · Cited by 66
Retroviral and Lentiviral Vectors for the Induction of Immunological Tolerance
Dufait, I., Liechtenstein, T., Lanna, A., Bricogne, C., Laranga, R., Padella, A., Breckpot, K., & Escors, D. (2012) · Scientifica · doi:10.6064/2012/694137 · Cited by 65
Gedeon, P. C., Schaller, T. H., Chitneni, S. K., Choi, B. D., Kuan, C., Suryadevara, C. M., Snyder, D. J., Schmittling, R. J., Szafranski, S. E., Cui, X., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0126 · Cited by 62
Intracavitary ‘T4 immunotherapy’ of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells
Klampatsa, A., Achkova, D., Davies, D. M., Parente‐Pereira, A. C., Woodman, N. L., Rosekilly, J., Osborne, G., Thayaparan, T., Billè, A., Sheaff, M., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.02.015 · Cited by 59
Yang, Q., Bavi, P. P., Wang, J. Y., & Roehrl, M. H. A. (2017) · Journal of Proteomics · doi:10.1016/j.jprot.2017.06.021 · Cited by 58
Siegler, E. L., Li, S., Kim, K. G., & Wang, P. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.021 · Cited by 58
Han, Y., Liu, C., Li, G., Li, J., Lv, X., Shi, H., Liu, J., Liu, S., Yan, P., Wang, S., et al. (2018) · PubMed · Cited by 58
Zhu, Q., Liu, M., Dai, L., Ying, X., Ye, H., Zhou, Y., Han, S., & Zhang, J. Y. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.06.015 · Cited by 54
Improving homing in T cell therapy
Vignali, D., & Kallikourdis, M. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.009 · Cited by 54
Grenga, I., Donahue, R. N., Gargulak, M. L., Lepone, L. M., Roselli, M., Bilušić, M., & Schlom, J. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.09.027 · Cited by 52
Hong, H., Brown, C. E., Ostberg, J. R., Priceman, S. J., Chang, W.-C., Weng, L., Lin, P., Wakabayashi, M. T., Jensen, M. C., & Forman, S. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146885 · Cited by 48
Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies
Hoseini, S. S., & Cheung, N. V. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.04.013 · Cited by 48
Bräunlein, E., & Krackhardt, A. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01702 · Cited by 48
CD44v6 as innovative sarcoma target for CAR-redirected CIK cells
Leuci, V., Casucci, M., Grignani, G., Rotolo, R., Rossotti, U., Vigna, E., Gammaitoni, L., Mesiano, G., Fiorino, E., Donini, C., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1423167 · Cited by 48
T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma
Singh, N., Kulikovskaya, I. M., Barrett, D. M., Binder-Scholl, G. K., Jakobsen, B. K., Martínez, D., Pawel, B., June, C. H., Kalos, M. D., & Grupp, S. A. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1040216 · Cited by 46
Fang, Z., Wen, C., Chen, X., Yin, R., Zhang, C., Wang, X., & Huang, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.17013 · Cited by 45
Merker, M., Pfirrmann, V., Oelsner, S., Fulda, S., Klingebiel, T. E., Wels, W. S., Bader, P., & Rettinger, E. (2017) · Oncotarget · doi:10.18632/oncotarget.19821 · Cited by 42
Yang, Q., Roehrl, M. H. A., & Wang, J. Y. (2017) · Oncotarget · doi:10.18632/oncotarget.23583 · Cited by 42
Wu, X., Giobbie‐Hurder, A., Connolly, E. M., Li, J., Liao, X., Severgnini, M., Zhou, J. M., Rodig, S. J., & Hodi, F. S. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1440930 · Cited by 42
Bronte, G., Incorvaia, L., Rizzo, S., Passiglia, F., Galvano, A., Rizzo, F., Rolfo, C. D., Fanale, D., Listì, A., Natoli, C., et al. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.08.011 · Cited by 38
Aguirrechu, I. C. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00263 · Cited by 27
VEGFR2-specific FnCAR effectively redirects the cytotoxic activity of T cells and YT NK cells
Kulemzin, S. V., Gorchakov, A. A., Chikaev, A. N., Kuznetsova, V., Volkova, O. Y., Matvienko, D. A., Petukhov, A., Zaritskey, A. Y., & Taranin, A. V. (2018) · Oncotarget · doi:10.18632/oncotarget.24078 · Cited by 25
Engineered T lymphocytes eliminate lung metastases in models of pancreatic cancer
Sun, Q., Zhou, S., Zhao, J., Deng, C., Teng, R., Zhao, Y., Chen, J., Dong, J., Yin, M., Bai, Y., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24122 · Cited by 21
Starving for survival—how catabolic metabolism fuels immune function
Balmer, M. L., & Hess, C. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.03.009 · Cited by 19
Editorial overview: Metabolism of T cells: integrating nutrients, signals, and cell fate
MacIver, N. J., & Rathmell, J. C. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.06.002 · Cited by 17
Valentini, D., Rao, M., Meng, Q., von Landenberg, A., Bartek, J. J., Sinclair, G., Paraschoudi, G., Jäger, E., Peredo, I. H., Dodoo, E., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24955 · Cited by 17
van den Brom, R. R. H., van der Geest, K. S. M., Brouwer, E., Hospers, G. A. P., & Boots, A. M. H. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2148-6 · Cited by 15
Xie, J., Zhou, Z., Jiao, S., & Li, X. (2018) · Oncology Letters · doi:10.3892/ol.2018.8617 · Cited by 11
Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma
Liu, Z., Rao, M., Poiret, T., Nava, S., Meng, Q., von Landenberg, A., Bartek, J. J., Xie, S., Sinclair, G., Peredo, I. H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20303 · Cited by 10
Cited by
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Tumor Immunology and Tumor Evolution: Intertwined Histories
Galon, J., & Bruni, D. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.018 · Cited by 540
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Albelda, S. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00832-4 · Cited by 517
Immunotherapy: Reshape the Tumor Immune Microenvironment
LV, B., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 482
Colorectal Cancer Immunotherapy: Options and Strategies
Johdi, N. A., & Sukor, N. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01624 · Cited by 452
Metadata
- Authors
- Martinez, M., & Moon, E. K.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-02-05
- Volume
- 10
- Pages
- 128-128
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2911543360
- Cited by
- 851
- References
- 190
- FWCI
- 40.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.